

Supplement table 1. Baseline characteristics of patients receiving endovascular treatment.

Characteristic	Patients (n=300)
Age, y, mean (SD)	58.3 (9.78)
Male sex	228 (76.0%)
Risk factors	
Hypertension	215 (71.7%)
Hyperlipidemia	121 (41.3%)
Diabetes mellitus	90 (30.0%)
Smoking history	
Current	78 (26.0%)
Former	88 (29.3%)
Never	134 (44.7%)
Obesity	23 (7.7%)
BMI, mean (SD)	25.6 (3.02)
Blood pressure, mm Hg, mean (SD)	
Systolic	138.9 (17.42)
Diastolic	83.4 (12.10)
Cholesterol, mg/dL, mean (SD)	
Low-density lipoprotein	89.2 (36.42)
High-density lipoprotein*	39.7 (10.66)
Qualifying ischemic events	
TIA	137 (45.7%)
Stroke	163 (54.3%)
Symptomatic qualifying artery	
BA	94 (31.3%)
Intracranial vertebral	73 (24.3%)
MCA	91 (30.3%)
Intracranial carotid	42 (14.0%)
Imaging modalities for evaluation of hemodynamic impairment before endovascular treatment	
Perfusion CT	156 (52.0%)

DSA	122 (40.6%)
MRI	22 (7.3%)
Time from qualifying event to endovascular treatment, days	
Median	21
Interquartile range	10-34
Cases with loading dose of clopidogrel	26 (8.7%)
Arterial stenosis, %, mean (SD)	84.3 (7.51)

BMI denotes body mass index; TIA denotes transient ischemic attack; BA denotes basilar artery; MCA denotes middle cerebral artery; CT denotes computer tomography; DSA denotes digital subtraction angiogram; MRI denotes magnetic resonance imaging. *The data came from 295 patients with available high-density lipoprotein.

Supplement table 2. Comparison baseline characteristics between patients balloon mounted stenting and balloon predilation plus self-expanding stenting

Characteristic	Patients treated with balloon mounted stenting (n=159)	Patients treated with balloon predilation plus self-expanding stenting (n=141)	<i>P</i> Value
Age, y, mean (SD)	59.4 (9.51)	57.0 (9.95)	0.034
Male sex	120 (75.5%)	108 (76.6%)	0.892
Risk factors			
Hypertension	110 (69.2%)	105 (74.5%)	0.369
Hyperlipidemia	60 (37.7%)	61 (43.3%)	0.347
Diabetes mellitus	53 (33.3%)	37 (26.2%)	0.207
Smoking history			
Current	43 (27.0%)	35 (24.8%)	0.694
Former	45 (28.3%)	43 (30.5%)	0.704
Never	71 (44.7%)	63 (44.7%)	1.000
Obesity	15 (9.4%)	8 (5.7%)	0.279
BMI, mean (SD)	25.7 (3.14)	25.5 (2.88)	0.669
Blood pressure, mm Hg, mean (SD)			
Systolic	137.1 (15.80)	141.0 (18.92)	0.056
Diastolic	83.2 (13.53)	83.6 (10.30)	0.805
Cholesterol, mg/dL, mean (SD)			
Low-density lipoprotein	86.3 (37.28)	92.5 (35.27)	0.141
High-density lipoprotein*	39.4 (11.37)	40.1 (9.58)	0.540
Qualifying ischemic events			
TIA	75 (47.2%)	62 (44.0%)	0.643
Stroke	84 (52.8%)	79 (56.0%)	0.643
Symptomatic qualifying artery			
BA	48 (30.2%)	46 (32.6%)	0.709
Intracranial vertebral	48 (30.2%)	25 (17.7%)	0.015

MCA	38 (23.9%)	53 (37.6%)	0.012
Intracranial carotid	25 (15.7%)	17 (12.1%)	0.407
Time from qualifying event to endovascular treatment, days			
Median	20	22	
Interquartile range	9-34	11-33	0.763
Cases with loading dose of clopidogrel	18 (11.3%)	8 (5.7%)	0.101
Arterial stenosis,%, mean (SD)	84.0 (7.35)	84.7 (7.69)	0.436
Mori type			
Mori A	53 (33.3%)	27 (19.1%)	0.006
Mori B	83 (52.2%)	80 (56.7%)	0.486
Mori C	23 (14.5%)	34 (24.1%)	0.039
Anesthesia			
Local anesthesia	52 (32.7%)	48 (34.0%)	0.808
General anesthesia	107 (67.3%)	93 (66.0%)	0.808

BMI denotes body mass index; TIA denotes transient ischemic attack; BA denotes basilar artery; MCA denotes middle cerebral artery.*The data came from 295 patients with available high-density lipoprotein.

Supplement table 3. Comparison of baseline characteristics between patients with and without primary outcome.

Characteristic	Patients treated without composite primary endpoints (n=275)	Patients treated with composite primary endpoints (n=25)	Unadjusted HR	95% CI	P Value
Age, y, mean (SD)	58.1 (9.81)	61.0 (9.19)	1.032	0.989-1.076	0.150
Male sex	208 (75.6%)	20 (80.0%)	0.790	0.296-2.104	0.636
Risk factors					
Hypertension	199 (72.7%)	16 (64.0%)	0.698	0.308-1.579	0.388
Hyperlipidemia	113 (41.1%)	8 (32.0%)	0.688	0.297-1.593	0.382
Diabetes mellitus	86 (31.3%)	4 (16.0%)	0.436	0.150-1.269	0.128
Smoking history					
Current	72 (26.2%)	6 (24.0%)	0.887	0.354-2.220	0.797
Former	81 (29.5%)	7 (28.0%)	0.943	0.394-2.257	0.895
Never	122 (44.4%)	12 (48.0%)	0.870	0.397-1.906	0.727
Obesity	23 (8.4%)	0 (0%)	0.044	0.000-25.638	0.336
BMI, mean (SD)	25.6 (3.03)	25.3(2.94)	0.963	0.846-1.096	0.570
Blood pressure, mm Hg, mean (SD)					
Systolic	138.7 (17.32)	140.6 (18.75)	1.005	0.983-1.027	0.649
Diastolic	83.4 (12.22)	83.0 (10.91)	0.997	0.965-1.031	0.876
Cholesterol, mg/dL,mean (SD)					
Low-density lipoprotein	89.4(35.89)	87.1(42.64)	0.998	0.987-1.010	0.791
High-density lipoprotein*	39.9(10.71)	37.6(10.01)	0.979	0.940-1.020	0.310
Qualifying ischemic events (Stroke)	150 (54.5%)	13 (52.0%)	0.905	0.413-1.984	0.804
Symptomatic qualifying artery					
BA	85 (30.9%)	9 (36.0%)	1.259	0.556-2.849	0.580
Intracranial vertebral	69 (25.1%)	4 (16.0%)	0.574	0.197-1.673	0.309
MCA	82 (29.8%)	9 (36.0%)	1.302	0.575-2.946	0.527
Intracranial carotid	39 (14.2%)	3 (12.0%)	0.835	0.250-2.790	0.770
Time from qualifying event to endovascular treatment, days , median	21(10.0-34.0)	18 (8.0-30.5)	0.999	0.969-1.010	0.315

	(Interquartile range)				
Cases with loading dose of clopidogrel	24 (8.7%)	2 (8.0%)	0.897	0.211-3.803	0.882
Arterial stenosis, %, mean (SD)	84.4(7.58)	84.0(6.81)	0.993	0.942-1.046	0.778
Mori type					
Mori A	75 (27.3%)	5 (20.0%)	0.692	0.260-1.844	0.462
Mori B	149 (54.2%)	14 (56.0%)	1.059	0.481-2.333	0.886
Mori C	51 (18.5%)	6 (24.0%)	1.356	0.542-3.395	0.516
General anesthesia	180 (65.5%)	20 (80.0%)	2.036	0.764-5.425	0.155
Residual stenosis, %, mean (SD)	8.6 (8.10)	8.0 (8.41)	0.991	0.943-1.042	0.736
Balloon mounted stent	145 (52.7%)	14 (56.0%)	0.893	0.405-1.967	0.779

BMI denotes body mass index; TIA denotes transient ischemic attack; BA denotes basilar artery; MCA denotes middle cerebral artery.*The data came from 295 patients with available high-density lipoprotein.